<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889638</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00224186</org_study_id>
    <secondary_id>UL1TR003098</secondary_id>
    <nct_id>NCT04889638</nct_id>
  </id_info>
  <brief_title>Tobacco Cessation in Public Housing</brief_title>
  <official_title>Comprehensive Tobacco Cessation for Residents of Baltimore City Public Housing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Community Partnership and Collaboration Core Pilot Grant</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inequity in cessation resources is at forefront in the recently enacted nationwide&#xD;
      smoking ban in public housing facilities. The critical component lacking from the federal&#xD;
      decree was a practical smoking cessation strategy to address the real-world needs of active&#xD;
      smokers who maintain cigarette usage. The investigator's proposal is ideally situated for&#xD;
      this contemporary moment when low-income smokers in public housing are signing leases&#xD;
      describing the potential for smoking-related evictions and thus at least contemplating&#xD;
      smoking modification. The investigator's project is centered around the residents of&#xD;
      Baltimore City Public Housing which is among the larger-sized U.S. public housing agencies.&#xD;
      Using a human-centered design (HCD) approach, the investigators are refining and testing a&#xD;
      community-centric cessation strategy defined by two core elements: a) durable and jointly&#xD;
      linked community/hospital infrastructure systems (remote cessation specialist staffing and&#xD;
      drug supplies) and strong on-site (public housing) residential leadership commitment to&#xD;
      cessation improvement. These dual features, along with adaptable elements that can be&#xD;
      modified to a variety of local/national housing settings, defines how the investigator's&#xD;
      project will overcome the implementation gaps defining failed smoking cessation efforts in&#xD;
      lower-income settings. The objective of this project is to test the feasibility of the&#xD;
      intervention package among local housing contextual factors that could impact both the&#xD;
      acceptability and adoptability of the investigator's project. Using a collection of formative&#xD;
      and implementation evaluation measures, the investigator's academic-community partnership&#xD;
      project is well positioned to create an adaptable and customizable intervention that can be&#xD;
      scaled in similar housing populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lower socioeconomic populations continue to remain at high risk for tobacco use and suffer&#xD;
      disproportionately from tobacco-related disease. Evidence is lacking of ways to optimally&#xD;
      deliver behavioral and pharmaceutical-based cigarette smoking cessation interventions in&#xD;
      real-world environments among disadvantaged cohorts where geographic, socioeconomic and&#xD;
      technological disparities often undermine the effectiveness of evidence-based smoking&#xD;
      cessation efforts. The investigator's study focuses on residents of public housing in&#xD;
      Baltimore City, a population who face multiple socioeconomic stressors and of whom up to 1/3&#xD;
      are assumed conventional cigarette users.&#xD;
&#xD;
      The investigator's project uses a partnership between the Housing Authority of Baltimore City&#xD;
      (HABC) and Johns Hopkins School of Medicine to enact a remote (off-site) cessation program in&#xD;
      two public housing complexes under the management of HABC. The investigator's program will&#xD;
      institute evidence-based practices in an accessible manner for the residents at both sites.&#xD;
      The investigator's program's key features include the remote recruitment, prescription,&#xD;
      delivery and management of evidence-based nicotine pharmacotherapies, and provision of&#xD;
      cessation counseling.&#xD;
&#xD;
      To assess the feasibility of study design, the investigator's project specifically focuses on&#xD;
      the following eight elements: a) recruitment of smokers expressing a motivation to reduce or&#xD;
      quit smoking, b) Consent process, c) nicotine and non-nicotine pharmacotherapy selection,&#xD;
      screening, prescription, delivery, storage management (participation education,&#xD;
      side-effecting monitoring), and return of unused drug supplies, d) Administration and&#xD;
      perceived utility of motivational interviewing regarding smoking reduction and cessation, e)&#xD;
      Delivery of study reimbursement, f) Utility of weekly text reminders of study participation&#xD;
      and final endpoint, g) acceptability of outcome measures, h) acceptability and evaluation of&#xD;
      joint project oversight with community stakeholders.&#xD;
&#xD;
      The project will enroll eighty participants to determine feasibility endpoints. All&#xD;
      participants will receive the intervention, as preferred by community partners. Participants&#xD;
      will serve as their own control, which in turn means that the investigators will compare the&#xD;
      intervention's effect at an individual level. All participants will be offered over a 4-week&#xD;
      period both a long-acting nicotine controller medication (varenicline or nicotine patch) and&#xD;
      short-acting medication to address acute urges to smoke (nicotine gum/lozenge). Each week&#xD;
      participants will be monitored and receive cessation-directed counseling. If medication&#xD;
      questions or concerns arise, patients will have access to 24-hour phone support. The results&#xD;
      of the project will be reviewed with participants, community partners and academic team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pre-post study design</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System (PROMIS) Nicotine Dependence (Short Form 8a)</measure>
    <time_frame>Change from baseline to week four</time_frame>
    <description>This outcome measures assesses cravings or withdrawal that occurs upon brief cessation of smoking, smoking temptations, compulsive use, and tolerance.&#xD;
The scores range from 8 - 40. The lower end of the range indicates no nicotine dependence and the upper end of the range correlates with a high degree of dependence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PROMIS Coping Expectancies (Short Form 4a)</measure>
    <time_frame>Change from baseline to week four</time_frame>
    <description>This outcome measure assesses smokers' tendency to use smoking as a means of coping with negative affect and stress.&#xD;
The scores range from 4 - 20. A score of 4 indicates cigarettes are not being used to cope with life experience and mental health; a maximum of 20 indicates cigarettes are being used always or very much to address both negative life experiences and mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Emotional and Sensory Expectancies (Short Form 6a)</measure>
    <time_frame>Change from baseline to week four</time_frame>
    <description>This outcome measure assesses perceptions of improved cognitive abilities, positive affective states, and pleasurable sensorimotor sensations due to smoking.&#xD;
The scores range from 6 - 30. A score of 6 indicates cigarettes are not being used to enhance emotional and sensory experiences; a maximum of 30 indicates cigarettes are strongly (or very much) used to improve both emotional and sensory experiences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Health Expectancies (Short Form 6a)</measure>
    <time_frame>Change from baseline to week four</time_frame>
    <description>This outcome measure assesses perceptions of improved cognitive abilities, positive affective states, and pleasurable sensorimotor sensations due to smoking.&#xD;
The scores range from 6 - 30. A score of 6 indicates smoking cigarettes are not perceived at all as being associated with negative health experiences, including changes in cognition, affect and sensorimotor sensations; a score of 30 translates to a perception that cognition, affect and sensorimotor sensations are very much associated with smoking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Psychosocial Expectancies (Short Form 6a)</measure>
    <time_frame>Change from baseline to week four</time_frame>
    <description>This outcome measure assesses smokers' beliefs about aspects of social disapproval and disappointment in oneself that are experienced as a result of smoking.&#xD;
The scores range from 6 - 30. A score of 6 indicates smoking cigarettes are not perceived at all as being associated with social disapproval and disappointment in oneself; a score of 30 translates to a perception that smoking is very much associated with social disapproval and disappointment in oneself</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Social Motivations (Short Form 4a)</measure>
    <time_frame>Change from baseline to week four</time_frame>
    <description>This outcome measure assesses smokers' assesses self-reported social factors that influence smoking behavior.&#xD;
The range of scores is from 4 - 20. A score of 4 indicates there is not any perceived association between smoking and social factors; a score of 20 indicates a very strong perception that smoking is associated with social factors.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Smoking Reduction</condition>
  <condition>Smoking, Tobacco</condition>
  <arm_group>
    <arm_group_label>Cessation intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo pre-/post-comparisons of a personalized, remote smoking cessation intervention composed of two main elements: a) prescription and monitoring of nicotine (e.g., replacement therapy) and/or non-nicotine pharmacotherapies (e.g., varenicline) and b) cessation-centered motivational messaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cessation Intervention</intervention_name>
    <description>Pharmacotherapy selection, prescription and monitoring of up to two types of cessation pharmacotherapies: Nicotine replacement therapy (gum, lozenge and transdermal patch) and non-nicotine replacement therapy (varenicline).&#xD;
Remote video-conferencing and mobile phone-based, personalized motivational messaging</description>
    <arm_group_label>Cessation intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥18 years of age&#xD;
&#xD;
          -  Self-reported smoker with either daily or weekly cigarette use, as well as expressed&#xD;
             desire to reduce or quit smoking&#xD;
&#xD;
          -  Proof of residence at Douglass or Brooklyn Homes through verbal acknowledgement by the&#xD;
             Service Coordinators at each of the public housing sites.&#xD;
&#xD;
          -  Working cell phone with texting ability for the duration of the study&#xD;
&#xD;
          -  Active health insurance (for pharmacotherapy billing)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant - women will verbally acknowledge that they are not pregnant&#xD;
&#xD;
          -  Breastfeeding - women who are verbally acknowledge they are breastfeeding will be&#xD;
             excluded from the study.&#xD;
&#xD;
          -  Ongoing participation in a tobacco cessation program or related tobacco intervention&#xD;
             study&#xD;
&#xD;
          -  Unable to verbally state that they are willing to reduce or quit smoking upon&#xD;
             recruitment and screening&#xD;
&#xD;
          -  Adults lacking capacity to consent&#xD;
&#xD;
          -  Non-English speakers&#xD;
&#xD;
          -  Self-reported usage of only non-combustible tobacco products, such as smokeless&#xD;
             tobacco or Electronic Nicotine Delivery Devices (ENDS).&#xD;
&#xD;
          -  Anticipated relocation outside of Douglass or Brooklyn Homes prior to the final study&#xD;
             visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mandeep S. Jassal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mandeep S. Jassal, MD, MPH</last_name>
    <phone>4109552035</phone>
    <email>mjassal1@jhmi.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

